Sarepta Therapeutics: A Strong Opportunity Amidst The Panic

Following a tumultuous period, it looks like Sarepta Therapeutics (NASDAQ: SRPT ) has stabilised. Now available at a historic discount and a steep discount to fair value, investors should consider buying the biotech. With strong patient support, Sarepta has reached a resolutionL/S Equity strategy in SMID cap biotech. We have a strong emphasis on thorough modelling for new drugs and often look for de-risked but overlooked assets. For many more ideas, especially short theses, please refer to our website (exci ...